Blog
RSS FeedPosted by Michael Wonder on 20 Dec 2023
Ravulizumab for the treatment of patients with generalised myasthenia gravis
20 December 2023 - NICE is unable to make a recommendation on the use of ravulizumab (Ultomiris) for the treatment of ...
Posted by Michael Wonder on 19 Dec 2023
The Government of Canada announces the creation of the Canadian Drug Agency
18 December 2023 - Helping make Canada's drug system more sustainable and better prepared for the future. ...
Posted by Michael Wonder on 17 Dec 2023
Recommendations made by the PBAC (November 2023)
18 December 2023 - Recommendations made by the PBAC in November 2023 relating to the listing of medicines on the ...
Posted by Michael Wonder on 16 Dec 2023
Report on the collection of under co-payment data 2022-23
15 December 2023 - The report on the collection of under co-payment data 2022-23 is now available. ...
Posted by Michael Wonder on 15 Dec 2023
CSL Behring’s Hemgenix granted first ever direct access in France for haemophilia B gene therapy
13 December 2023 - CSL Behring has been granted Direct Access for Hemgenix (etranacogene dezaparvovec) by the French Ministry of ...
Posted by Michael Wonder on 13 Dec 2023
Velmanase alfa for the treatment of patients with alfa mannosidosis
13 December 2023 - NICE has published final evidence-based recommendations on the use of velmanase alfa (Lamzede) for treatment of ...
Posted by Michael Wonder on 13 Dec 2023
Pembrolizumab and chemotherapy with or without bevacizumab for patients with persistent, recurrent or metastatic cervical cancer
13 December 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) and chemotherapy with or ...
Posted by Michael Wonder on 12 Dec 2023
Efgartigimod for the treatment of patients with generalised myasthenia gravis (draft guidance 2)
12 December 2023 - NICE has published further draft guidance on the use of efgartigimod for the treatment of patients ...
Posted by Michael Wonder on 12 Dec 2023
PHARMAC proposes to fund treatments for breast and blood cancer
12 December 2023 - PHARMAC is seeking feedback on a proposal to fund two new treatments for advanced breast cancer and ...
Posted by Michael Wonder on 11 Dec 2023
SMC - December 2023 decisions
11 December 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 11 Dec 2023
Cheaper medicines for breast cancer, small cell lung cancer, biliary tract cancer, juvenile idiopathic arthritis and Crohn's disease
11 December 2023 - From 1 December 2023, Australians with small cell lung cancer, biliary tract cancer, juvenile idiopathic arthritis and ...
Posted by Michael Wonder on 09 Dec 2023
Medicines lobby says the PBS has not kept up with advances — or approvals — in medicines
8 December 2023 - Little Jack Roche was five weeks old when diagnosed with cystic fibrosis. The medication that could help ...
Posted by Michael Wonder on 07 Dec 2023
Updates to the HTA Policy and Methods Review Reference Committee (8 December 2023)
8 December 2023 - The agenda for the HTA Review Reference Committee meeting (meeting 29) held on 1 December 2023 is ...
Posted by Michael Wonder on 07 Dec 2023
Evolving our approach to COVID-19 vaccines and treatments
6 December 2023 - As New Zealand’s response to the COVID-19 pandemic has evolved, so has ours. ...
Posted by Michael Wonder on 07 Dec 2023
Dupilumab for the treatment of patients with eosinophilic oesophagitis
7 December 2023 - NICE is unable to make a recommendation on the use of dupilumab (Dupixent) for the treatment of ...